Biocryst Pharmaceuticals (BCRX) Change in Cash (2010 - 2026)

Biocryst Pharmaceuticals has reported Change in Cash for 17 years, with the latest figure at $82.0 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Cash rose 14602.69% year-over-year to $82.0 million; the trailing twelve-month figure through Mar 2026 stood at $66.5 million (up 220.47% YoY), and the FY2025 full-year result was -$15.0 million, down 144.71% from the prior year.
• Change in Cash for Q1 2026 stood at $82.0 million, up from -$9.6 million in the prior quarter.
• The five-year high for Change in Cash was $82.0 million in Q1 2026, with the low at -$149.6 million in Q1 2023.
• Historically, Change in Cash has averaged -$19.7 million across 5 years, with a median of -$5.9 million in 2024.
• Annual changes were most pronounced in 2022 — Change in Cash slumped 668.33% — and 2026, when it jumped 14602.69%.
• Biocryst Pharmaceuticals' Change in Cash stood at $57.9 million in 2022, then slumped by 169.16% to -$40.0 million in 2023, then jumped by 118.13% to $7.3 million in 2024, then slumped by 231.7% to -$9.6 million in 2025, then jumped by 958.17% to $82.0 million in 2026.
• The last three Change in Cash figures came in at $82.0 million (Q1 2026), -$9.6 million (Q4 2025), and -$4.1 million (Q3 2025), per Business Quant data.